Response to Difenciprone in Alopecia Areata of Difficult Treatment: Case Report.

Abstract

Abstract:

Introduction. Currently alopecia areata (AA) is considered an autoimmune disease with a genetic substrate, dependent on T cells and organ-specific, factor, autoimmune and emotional stress, and topical difenciprone has been the treatment of choice in extensive Alopecia Areata. Objective. To present a case report of a clinical response to Difenciprone in AA that is difficult to treat. Methodology. Patient, 23 years old, female, with AA, submitted to topical immunotherapy with Difenciprone (DPCP), under the following concentrations: 2%, 0.001%, 0.005%, 0.01%, 0.05%, and 0.075%, over a period of 18 months, and at the end, Minoxidil 1 mg/day orally and clobetasol propionate 0.05% cream for 20 days were associated. Results The patient presented with a start of repilation after two months of treatment, tolerating a concentration of up to 0.05%, after which she presented side effects such as eczema in the upper limbs and trunk corroborating the scientific findings in the literature. Conclusions. The extent of alopecia and disease duration are important factors in predicting the response to treatment. The efficacy of contact immunotherapy with Difenciprone has a variable response, but it is a safe and effective option in the treatment of AA. Its use must be made in a prolonged way, reduction of the drug must be carried out gradually.